✦ LIBER ✦

OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer

✍ Scribed by G. de Lima Lopes; J. Segel; D. Tan; Y. Do; T. Mok; E. Finkelstein

Book ID: 119233810
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 34 KB
Volume: 9
Category: Article
ISSN: 1359-6349
DOI: 10.1016/j.ejcsup.2011.02.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of epidermal growth f

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung

✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven

Gefitinib as first-line treatment for pa

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 216 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION TESTING AND FIRST LINE TREATMENT WITH GEFITINIB IS A DOMINANT STRATEGY IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Gefitinib as first-line treatment for pa

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues

✍ Gridelli, C.; De Marinis, F.; Di Maio, M.; Cortinovis, D.; Cappuzzo, F.; Mok, T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 144 KB

PMD19 COST-EFFECTIVENESS OF EPIDERMAL GR

PMD19 COST-EFFECTIVENESS OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE MUTATION TESTING IN THE SELECTION OF FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER IN ONTARIO

✍ W. Chen; P. Ellis; L. Levin; M. Krahn 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

PCN34 COST-EFFECTIVENESS OF GEFITINIB FO

PCN34 COST-EFFECTIVENESS OF GEFITINIB FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: A MARKOV MODEL-BASED ANALYSIS

✍ PH Liu; FC Hu; JD Wang 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB